Company Encyclopedia
View More
name
Nektar Therap
NKTR.US
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.
4.514 T
NKTR.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking132/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-180.24%E
    • Profit Margin-192.87%E
    • Gross Margin100.00%A
  • Growth ScoreD
    • Revenue YoY-32.79%E
    • Net Profit YoY28.26%B
    • Total Assets YoY-2.15%D
    • Net Assets YoY74.06%A
  • Cash ScoreE
    • Cash Flow Margin-51.85%D
    • OCF YoY-32.79%E
  • Operating ScoreD
    • Turnover0.21D
  • Debt ScoreD
    • Gearing Ratio71.76%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Nektar Therapeutics shares are trading higher after Citigroup initiated coverage on the stock with a Buy rating and announced a $102 price target.

    benzinga_article·
    US
    NKTR
    +0.98%
    benzinga_article·
    US
    NKTR
    +0.98%

    VP Zalevsky Acquires 1,509 Of Nektar Therapeutics [NKTR]

    Jonathan Zalevsky, Vice President of Nektar Therapeutics, filed a Form 4 with the SEC on November 25, 2025, disclosing changes in ownership. He exercised 2,666 shares and surrendered 1,157 shares at $54.28 each to cover option exercise costs and/or tax liabilities. His ending holdings are 18,971 shares directly. This transaction is part of insider trading activities.

    Reuters·
    US
    NKTR
    +0.98%
    Reuters·
    US
    NKTR
    +0.98%

    VP Wilson Surrenders 630 Of Nektar Therapeutics [NKTR]

    VP Mark Andrew Wilson of Nektar Therapeutics surrendered 630 shares back to the company to cover option exercise costs and/or tax liabilities. The transaction was filed with the SEC on November 25, 2025, at a price of $54.28 per share, totaling $34,196. Wilson's ending direct holdings are 21,585 shares.

    Reuters·
    US
    NKTR
    +0.98%
    Reuters·
    US
    NKTR
    +0.98%

    Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Reports Sale of Common Shares

    Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, has reported the sale of common shares, as per an SEC filing. This event is significant for the company and its stakeholders.

    Reuters·
    US
    NKTR
    +0.98%
    Reuters·
    US
    NKTR
    +0.98%

    CEO Robin Surrenders 2,207 Of Nektar Therapeutics [NKTR]

    Robin Howard, CEO of Nektar Therapeutics, surrendered 2,207 shares back to the company to cover option exercise costs and/or tax liabilities. This transaction was disclosed in a Form 4 filed with the SEC on November 25, 2025. The shares were valued at $119,796, with an ending holding of 54,273 shares.

    Reuters·
    US
    NKTR
    +0.98%
    Reuters·
    US
    NKTR
    +0.98%
    © 2025 Longbridge｜Disclaimer